Functional Foods Business
Only One Material for People's Health
In order to manufacture safe and high quality products based on our cultivation technology cultivated for over 50 years, we manufacture our products in a hygienic environment and management methods in accordance with Good Manufacturing Practice (GMP) for dietary supplements, including a series of manufacturing processes and quality inspections, to ensure the safety of our products. We strive to ensure that our products are safe and effective. We are committed to providing reliable quality for your valuable products.
Functional Foods Business
Only One Material for People's Health
In order to manufacture safe and high quality products based on our cultivation technology cultivated for over 50 years, we manufacture our products in a hygienic environment and management methods in accordance with Good Manufacturing Practice (GMP) for dietary supplements, including a series of manufacturing processes and quality inspections, to ensure the safety of our products. We strive to ensure that our products are safe and effective. We are committed to providing reliable quality for your valuable products.
The nutritional components of Ganoderma lucidum are completely different from those of Extracts from Ganoderma lucidum mycelium culture medium containing special ingredients [MAK].
Developed in 1996, it is an extract of Ganoderma lucidum (another name for Mannentake), which has been prized since ancient times in China, based on a process of cultivating shiitake mushroom mycelium extracts.MAK is characterized by the presence of unique and useful substances produced by the Ganoderma lucidum mycelium in the process of metabolizing and growing on bagasse and rice bran in the culture medium.
The nutritional components of Ganoderma lucidum are completely different from those of Extracts from Ganoderma lucidum mycelium culture medium containing special ingredients [MAK].
Developed in 1996, it is an extract of Ganoderma lucidum (another name for Mannentake), which has been prized since ancient times in China, based on a process of cultivating shiitake mushroom mycelium extracts.MAK is characterized by the presence of unique and useful substances produced by the Ganoderma lucidum mycelium in the process of metabolizing and growing on bagasse and rice bran in the culture medium.
Bioactive components of MAK and their actions
Like LEM, MAK contains two types of active components, heteropolysaccharides and water-soluble lignin, both of which are produced by enzymes in the mycelium of the mycelium of Astragalus membranaceus, which also produces enzymes not found in the mycelium of shiitake mushroom. Heteropolysaccharides are composed mainly of pentasaccharides such as arabinose and xylose and hexasaccharides such as glucose. MAK also has a variety of actions, including antioxidant, brain damage protective, blood sugar elevation inhibitory, blood pressure elevation inhibitory, immunomodulatory, antiviral, and mood disorder ameliorating actions.
Bioactive components of MAK and their actions
Like LEM, MAK contains two types of active components, heteropolysaccharides and water-soluble lignin, both of which are produced by enzymes in the mycelium of the mycelium of Astragalus membranaceus, which also produces enzymes not found in the mycelium of shiitake mushroom. Heteropolysaccharides are composed mainly of pentasaccharides such as arabinose and xylose and hexasaccharides such as glucose. MAK also has a variety of actions, including antioxidant, brain damage protective, blood sugar elevation inhibitory, blood pressure elevation inhibitory, immunomodulatory, antiviral, and mood disorder ameliorating actions.
Safety of MAK
The mycelium used in the production of MAK is the same as that of the edible mannentake mushroom. Therefore, there are no safety issues. The safety of MAK has been confirmed through various safety tests, including toxicity and mutagenicity tests, conducted by an analytical laboratory.
| Acute toxicity | rat | Threshold dose study No abnormality |
NLT 22,500mg/kg |
| mouse | 2,000mg/kg | ||
| Mutagenicity | Negative | ||
| Repeated-dose study (three months) |
rat (male) | NOAEL | 3,610mg/kg/day |
| rat (fermale) | NOAEL | 4,190mg/kg/day | |
Safety of MAK
The mycelium used in the production of MAK is the same as that of the edible mannentake mushroom. Therefore, there are no safety issues. The safety of MAK has been confirmed through various safety tests, including toxicity and mutagenicity tests, conducted by an analytical laboratory.
| Acute toxicity | rat | Threshold dose study No abnormality |
NLT 22,500mg/kg |
| mouse | 2,000mg/kg | ||
| Mutagenicity | Negative | ||
| Repeated-dose study (three months) |
rat (male) | NOAEL | 3,610mg/kg/day |
| rat (fermale) | NOAEL | 4,190mg/kg/day | |
Examples of MAK Effectiveness Tests
▒ Antioxidant action
The 50% inhibitory concentration (ICso) was calculated for two antioxidant activities of MAK: O2 (superoxide anion) scavenging capacity and inhibition of lipid peroxide production. The results showed that MAK had antioxidant capacity comparable to that of vitamin C and vitamin E.
Examples of MAK Effectiveness Tests
▒ Antioxidant action
The 50% inhibitory concentration (ICso) was calculated for two antioxidant activities of MAK: O2 (superoxide anion) scavenging capacity and inhibition of lipid peroxide production. The results showed that MAK had antioxidant capacity comparable to that of vitamin C and vitamin E.
▒ Brain cell protective effects
Type I diabetic mice were divided into three groups: one group received MAK (0.3 or 1 g/kg) dissolved in distilled water orally and the other group received distilled water only. Administration was done once a day for 7 days. Half of the brains were then treated with hypoxia and observed for brain cell protection. The results showed that the formation of cerebral infarcts was inhibited in the MAK-treated group. In particular, the inhibitory effect was particularly high in the 1 g/kg dose group.
▒ Brain cell protective effects
Type I diabetic mice were divided into three groups: one group received MAK (0.3 or 1 g/kg) dissolved in distilled water orally and the other group received distilled water only. Administration was done once a day for 7 days. Half of the brains were then treated with hypoxia and observed for brain cell protection. The results showed that the formation of cerebral infarcts was inhibited in the MAK-treated group. In particular, the inhibitory effect was particularly high in the 1 g/kg dose group.
We can also provide you with samples of each raw material.
We can also provide you with samples of each raw material.